NewsRoom Articles - Page 78 of 154 - PsychedelicNewsWire (PNW)

FridayNov 19, 2021 1:30 pm

DEA Announces New Production Quotas for Psychedelic Substances for 2021, 2022

The DEA announced in September that it would be increasing the production quotas for Schedule I substances such as DMT, MDMA and psilocybin. This was after revealing the agency’s objective to produce more psychedelic substances for purposes of research next year. By the end of 2021, the DEA wants 6,000 grams of psilocybin to be manufactured, which is four times its last production quota. In its proposal, the agency states that the production quota for DMT and MDMA will be increased to 3,200 grams from 50 grams each. It also wants 2 million grams of cannabis to be produced this…

FridayNov 19, 2021 8:00 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Moves ‘One Step Closer’ to Creating Best Therapy for Mental Health

Company releases positive results from preclinical study focusing on psilocybin program CYB003 Multiple academic studies have shown that psilocybin may have the potential to revolutionize mental healthcare Results indicate less patient variability, faster onset of action, shorter duration of effect and improved brain penetration According to the National Institute of Mental Health, some 17.3 million Americans, or more than 7% of the country’s entire population, suffer from major depressive disorder (“MDD”) (https://ibn.fm/0GSuV). This demographic can look to Cybin (NEO: CYBN) (NYSE American: CYBN) for help; the pharmaceutical company has announced positive results from a preclinical study focusing on CYB003, one of…

ThursdayNov 18, 2021 11:00 am

Expert Says MDMA Could See FDA Approval by 2023

Associate professor Kelan Thomas of the Touro University California College of Pharmacy recently gave presentations during this year’s virtual Sana Symposium and the 2021 Insight conference that focused on the adverse effects of psychedelics and drug-drug interactions respectively. In a recent interview with Alana Hippensteele in the “Pharmacy Times,” Thomas was asked about his insights on the psychedelic space, with a focus on psychedelic medicine. When queried on the main points or common themes he’d observed in the field, Thomas stated that individuals were starting to consider the best practices to use psychedelics, noting that there was a lot of…

WednesdayNov 17, 2021 3:00 pm

Israel to Categorize Fibromyalgia as a Disability

Fibromyalgia is a disorder characterized by widespread muscle pain, which is often accompanied by mood issues, memory problems, sleep disturbances and fatigue. Some patients also experience cognitive difficulties and physical exhaustion. Now Israel plans to recognize the disorder as a disability, with the country’s Welfare and Social Affairs announcing in October that individuals suffering from the disorder will be recognized as disabled in a couple of weeks, which will allow them to claim disability allowance. This move will make Israel among the first nations around the globe to make provisions for patients with this condition. Data from the Israeli Fibromyalgia…

TuesdayNov 16, 2021 12:15 pm

Captivating Documentary Explores Psychedelics’ Role in PTSD Treatment

The focus on mental health has been growing as more research on psychedelic substances and their potential benefits as alternative treatments of various mental health conditions is conducted. Thus far, research has found that psychedelics such as mescaline, LSD and psilocybin mushrooms can help treat mental conditions, including depression, anxiety, addiction and post-traumatic stress disorder. Attention on this space has also been emphasized by the numerous literary works on the substances that are being published. A new documentary film on psychedelics, titled “Breaking Through,” which was directed and produced by Dan Laughton, a filmmaker based in London, is one of…

MondayNov 15, 2021 3:00 pm

Why Voices for Psychedelic Policy Change Are Getting Louder in Michigan

The city of Ann Arbor recently held its first Entheofest event. The festival is a commemoration of the city’s measure to decriminalize entheogenic fungi and plants, which was approved last year. The event featured speeches from activists, martial artists, musicians, healers, therapists, artists, community leaders, elected officials and researchers who discussed various topics, including research, health and the history of psychedelics. In an interview, codirector of Michigan’s Decriminalize Nature chapter Julie Barron stated that maintaining a personal relationship with entheogenic fungi and plant was a human right. Organizers noted that the festival was an opportunity to advocate for the legalization…

MondayNov 15, 2021 8:00 am

Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) Files Technology Patent Application Covering Bioavailability-Enhancing, Nanoemulsion-Empowered Formulations

Mydecine has filed a technology patent application that allows for the creation of nanoemulsion-empowered formulations to improve, stabilize, and increase the bioavailability of ingredients The company aims to use the nanoemulsion technology to enhance the bioavailability and optimize the delivery of compounds that are inspired by traditional ingredients In September, Mydecine filed its final patent application for MYCO-003, one of its lead drug candidates for enhanced treatment of anxiety and post-traumatic stress disorder MYCOF is steadily strengthening its IP portfolio as it seeks to reimagine the treatment of mental health and addiction Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF), an…

FridayNov 12, 2021 12:30 pm

Psychedelics May Play a Key Role in End-of-Life Care

Psychedelic drugs may revolutionize the health-care sector, in particular psychiatric treatment and end-of-life care, as more research on these substances is conducted. Substances such as ketamine, psilocybin, MDMA and LSD, which are still illegal in most parts of the country, have shown potential in the treatment of various mental health conditions including anxiety, depression, post-traumatic stress disorder and addiction. The potential of the psychedelic space has been noticed not only by researchers but also by venture capitalists and other investors who have been injecting billions into this burgeoning market in the hopes of getting it off the ground. Some of…

FridayNov 12, 2021 12:14 pm

Recent Sector News Reveals Positive Data in Psychedelic Treatments For Depression as Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Nears Launch of Synthetic Psilocybin Trials

Pharmaceutical company Tryp Therapeutics is developing a proprietary synthetic hallucinogen as potential medical solutions for select unmet health needs, with a focus on taking psychedelic therapeutics beyond mental health The company recently attended the Wonderland: Miami where Compass Pathways unveiled highly anticipated data from their Phase 2b trial in treatment-resistant depression Tryp’s Chairman and CEO Greg McKee served on a panel at Wonderland: Miami discussing the potential of synthetic psilocybin in chronic pain indications and the importance of supporting industry wins Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) Chairman and CEO Greg McKee recently participated in Microdose’s Wonderland: Miami conference as…

ThursdayNov 11, 2021 12:32 pm

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Launches Transformative Training Program for Psychedelic Facilitators

The EMBARK program represents the broad spectrum of ways in which therapeutic benefits might be experienced Program offers psychedelic clinical trial facilitators foundational training to provide skillful, ethical care to participants receiving psychedelic treatment EMBARK is built around open architecture to support varieties of psychedelic experience within a coherent therapeutic framework In a climate where psychedelic treatments are increasing in usage and acceptance, the importance of providing support and guidance in the space becomes even more important. With that in mind, Cybin (NEO: CYBN) (NYSE American: CYBN) has launched its proprietary EMBARK Psychedelic Facilitator Training Program (https://ibn.fm/3lzkp). Named for the program’s…

News and publishing service for psychedelic related companies

Contact us: 512.354.7000